First-line Chemotherapy for Recurrent Cervical Cancer
Status:
Recruiting
Trial end date:
2021-06-06
Target enrollment:
Participant gender:
Summary
The response rate of traditional first-line chemotherapy for recurrent or persistent advanced
cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible
patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23
patients. If at least 13 patients achieved complete or partial remission, the same regimen
would be given for rest patients. The primary end is overall response rate (ORR). The second
ends include progression-free survival, overall survival, disease control rate, remission
duration, and adverse events. A molecular testing, mainly consisting of genomic analysis,
will be carried in the oncologic tissues.